Recombinant porcine factor VIII use in bleed treatment in non-severe haemophilia A inhibitor patients: Dosing strategies and efficacy
Haemophilia
.
2021 Jan;27(1):e147-e150.
doi: 10.1111/hae.14111.
Epub 2020 Aug 25.
Authors
Patrick Ellsworth
1
2
,
Sheh-Li Chen
3
,
Nigel Key
1
,
Yasmina Abajas
2
,
Alice Ma
1
Affiliations
1
Division of Hematology-Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
2
Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of North Carolina, Chapel Hill, North Carolina, USA.
3
Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
PMID:
32842162
DOI:
10.1111/hae.14111
No abstract available
Publication types
Letter
MeSH terms
Animals
Factor VIII*
Hemophilia A* / complications
Hemophilia A* / drug therapy
Hemorrhage
Humans
Recombinant Proteins
Swine
Substances
Recombinant Proteins
Factor VIII
Grants and funding
T32 HL007149-37/UNC Benign Hematology T32